Nezapomínáme na možnost biologické terapie hypercholesterolemie pomocí PCSK9-inhibitorů?

Title in English Don't we forget about biological therapy of hypercholesterolemia with PCSK9-inhibitors?

SOŠKA Vladimír KYSELÁK Ondřej

Year of publication 2021
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Keywords atherosclerotic cardiovascular disease; familial hypercholesterolemia; LDL-cholesterol; statins; PCSK9-inhibitors
Description In many patients it is difficult to achieve the current very low target LDL-cholesterol levels, recommended for the prevention of atherosclerotic cardiovascular events. If statin therapy or statins in combination with ezetimibe are not sufficient, addition of PCSK9 inhibitors should be considered. PCSK9 inhibitors reduce LDL-CH by an average of 50-60 % and reduce the risk of atherosclerotic cardiovascular events. They are currently reserved for patients with atherosclerotic cardiovascular disease and for patients with familial hypercholesterolaemia, in whom despite intensive hypolipidemic therapy statins with ezetimibe the target LDL-cholesterol value is not reached. In these patients, PCSK9 inhibitors may also be indicated in case of statin intolerance.

You are running an old browser version. We recommend updating your browser to its latest version.

More info